Reta Stock News

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Enthralling stocks: Reata Pharmaceuticals, Inc. (NASDAQ:RETA -46.51%), Cleveland-Cliffs Inc. (NYSE:CLF -1.59%) appeared first on Stocks Equity .

An FDA panel rejected Reata Pharmaceuticals'' kidney disease treatment, bardoxolone, sending RETA stock into a tailspin on Thursday.

The FDA''s Cardiovascular and Renal Drugs Advisory Committee voted that the agency should not approve Reata Pharmaceuticals Inc''s (NASDAQ: RETA ) bardoxolone methyl capsules to slow the progression of chronic kidney disease in those with the rare Alport syndrome. Adcomm members largely agreed with the agency, citing safety concerns. Members of the committee also sought clarifications on why Reata Full story available on Benzinga.com

An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.

Today''s Daily Dose brings you news about the first antibody therapy for the prevention of COVID-19, the FDA panel review of Reata Pharma''s Alport syndrome drug; disappointing data from Radius Health''s wearABLe study; and encouraging new data of Zymeworks'' Zanidatamab in breast cancer.

Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) ("Reata," the "Company," or "we"), today announced the outcome of the U.S. Food and Drug Administration ("FDA") Cardiovascular and Renal Drugs Advisory Committee ("Committee") meeting on bardoxolone methyl ("bardoxolone") for the treatment of patients with chronic kidney disease ("CKD") caused by Alport syndrome. The Committee voted no on the question of whether the provided evidence demonstrated that bardoxolone is effective in slowing the progression of CKD in patients with Alport syndrome and that its benefits outweigh its risks. "We are disappointed with today''s outcome of the Committee''s vote regarding bardoxolone, an investigational drug with a novel mechanism of action," said Warren Huff, Reata''s President and Chief Executive Officer. "We believe the scientific evidence supports bardoxolone approval in the U.S. for CKD in patients with Alport syndrome, which is one of the most rapidly progressive forms of CKD. We will continue to work with the FDA to answer any questions they may have." While the FDA is not required to follow the committee''s vote, the agency considers the committee''s recommendations when making its decision.

SAN FRANCISCO, Dec. 8, 2021 /PRNewswire/ -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/RETA Contact An Attorney Now: [email protected] 844-916-0895 Reata Pharmaceuticals,

Reata Pharmaceuticals (NASDAQ:RETA) had its price target lowered by research analysts at Robert W. Baird from $212.00 to $110.00 in a research note issued on Monday, The Fly reports. The firm presently has an outperform rating on the stock. Robert W. Bairds price objective points to a potential upside of 102.13% from the stocks current []

SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now .

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Reata Pharmaceuticals, Inc. (Reata or the Company) (NASDAQ: RETA) investors concerning the Companys possible violations of federal securities laws. On December 6, 2021, the FDA released a briefing document regarding Reatas chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not demonstrate that bardoxolone is effective

LOS ANGELES--(BUSINESS WIRE)---- $RETA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

Briefing documents posted Monday suggest the FDA might not approve Reata Pharma''s kidney disease treatment and RETA stock plummeted.

The FDA has raised concerns about one of the company's key pipeline candidates in advance of a crucial meeting.